This HTML5 document contains 204 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n13http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n10https://w3id.org/oc/corpus/br/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q29620814
rdf:type
wikibase:Item
schema:description
artículo científico publicado en 2014 мақолаи илмӣ vedecký článok articol științific scienca artikolo 2014 nî lūn-bûn 2014年论文 บทความทางวิทยาศาสตร์ 2014年論文 tieteellinen artikkeli article scientifique 2014年論文 bilimsel makale naučni članak wetenschappelijk artikel (gepubliceerd op 2014/09/20) 2014年論文 2014年の論文 artikulong pang-agham teaduslik artikkel научни чланак artykuł naukowy scientific article (publication date: 20 September 2014) artigo científico мақолаи илмӣ article científic vitskapeleg artikkel 2014年论文 научная статья artículu científicu espublizáu en 2014 სამეცნიერო სტატია 2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած artigo científico tudományos cikk vetenskaplig artikel vitenskapelig artikkel 2014年论文 vědecký článek 2014년 논문 επιστημονικό άρθρο наукова стаття, опублікована у вересні 2014 2014年論文 mokslinis straipsnis artikull shkencor 2014年论文 bài báo khoa học wissenschaftlicher Artikel 2014年论文 ശാസ്ത്രപ്രബന്ധം​ מאמר מדעי 2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված научни чланак article scientific ২০১৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ videnskabelig artikel 2014年論文 artigo científico مقالة علمية (نشرت في 20-9-2014) 2014年论文 научна статия articolo scientifico
p:P577
wds:Q29620814-C2B0B1D0-6676-4224-9D8B-4D6436BAB183
wdt:P577
2014-07-15T00:00:00Z
p:P407
wds:Q29620814-6084B6AD-1FBF-4711-B8E2-FB2EA08B5A2A
wdt:P407
wd:Q1860
p:P2860
wds:Q29620814-FE2FC5F2-3858-4199-971F-39BCF02CBB40 wds:Q29620814-CFC28B5F-5D7F-4A8B-AD25-E75998C6340D wds:Q29620814-E5FCD302-89E5-45D2-AFD4-72357B34DAC4 wds:Q29620814-CAECF0A3-3E7B-4A79-B02C-BFC2AD4BE695 wds:Q29620814-C9300B68-D34B-4AA6-97B2-816D4A48AD5F wds:Q29620814-9BD80D2F-E2A4-489A-836F-C45422197223 wds:Q29620814-AF94FD04-3B10-4E4D-BFC0-6F43786F0185 wds:Q29620814-B501A8D1-85C6-4C33-BDD9-E386EB5057AB wds:Q29620814-955D6F85-58F7-4AA9-A476-7819EDD32B1D wds:Q29620814-9772B19C-C730-4662-9780-D969872E8905 wds:Q29620814-8FEA090E-B40F-4044-8FA5-E0A9B194EB60 wds:Q29620814-7B3D16A2-6297-40C8-93A5-C011172A0E1D wds:Q29620814-733D6596-AC8A-40D0-842D-29A90668310D wds:Q29620814-58215064-09DA-4331-9200-3830F7628A6B wds:Q29620814-5D8AD5DD-8EC8-40D6-8058-709AD6C249D0 wds:Q29620814-3A3FDCAC-0464-4AC1-AE87-EF1956BA3721 wds:Q29620814-42060117-B6C8-4AB1-BC73-850BC0A3FA6E wds:Q29620814-43E930F9-FC25-42F3-B4F6-0705CF2EDEF7 wds:Q29620814-453AE2A6-64B8-474F-ABE6-36E64C452263 wds:Q29620814-2C99C7E5-0066-47B0-BCAE-22AE992F8619 wds:Q29620814-277B035D-D843-4E9B-A5A3-0FDCAF8C2AB3 wds:Q29620814-29E2EE1C-A7DE-44A7-A0D9-DBFCB778C4A2 wds:Q29620814-19295F6D-0B8A-4FBC-9D9D-4B69AFFB97C9 wds:Q29620814-1DD29C78-A7D2-44FD-98B1-4569588BDBA0 wds:Q29620814-13ACBF0F-1244-48D3-B3AD-6DABE98B0C86 wds:Q29620814-01DB1F4B-F72F-4037-A6CE-8889BF2D4E61 wds:Q29620814-0B2D8FAD-24E1-4C7D-969F-C58A5EC71C88 wds:Q29620814-0B642D95-5968-45FF-B101-6C0DCE927A55
wdt:P2860
wd:Q30048279 wd:Q29620596 wd:Q29620663 wd:Q38163290 wd:Q29614756 wd:Q58024613 wd:Q37333645 wd:Q41501755 wd:Q24633549 wd:Q24594790 wd:Q27860852 wd:Q27276774 wd:Q46390622 wd:Q34637951 wd:Q41051660 wd:Q56873131 wd:Q27860857 wd:Q24293504 wd:Q37088281 wd:Q27860650 wd:Q27852310 wd:Q28131650 wd:Q28131668 wd:Q24633070 wd:Q27861062 wd:Q24632064 wd:Q24631953 wd:Q28265610
p:P2093
wds:Q29620814-5F02E0BF-E1D4-42B8-9C08-33B47A53CEFC wds:Q29620814-BF112012-FED3-4423-94D5-3541723B943B wds:Q29620814-D8FFF564-3217-4892-B06D-6AA44954A26E wds:Q29620814-D68E3A2A-8120-45C6-907B-094E65B68ACE wds:Q29620814-CA6E8EC5-0F9C-4814-973B-5B74C7B5CA4E wds:Q29620814-068CC94A-3EDC-453A-B85E-A1627C3C6ABB wds:Q29620814-20F0FCF6-496A-4D02-AA87-0A5B5EA7D9E9 wds:Q29620814-13A18258-AC67-40B4-8E50-3E5421F45923 wds:Q29620814-0EAC9A90-9304-4270-A328-0AA77767C5FC wds:Q29620814-0ECDA9DE-AC6D-4679-8CCF-81757CF3FF3B wds:Q29620814-6697DDA4-71F7-4B4B-8A23-8FBE16257EA3 wds:Q29620814-6406462F-B2DB-4C09-9E35-EB6D64192A78 wds:Q29620814-8702EECD-D442-4E06-B862-81703ED0E76B wds:Q29620814-754F2D97-B79F-4816-B4BC-A9C293ABFC11
p:P3181
wds:Q29620814-349AFD52-2391-4BE4-B028-DF8741EBBC82
wdtn:P3181
n10:42134
wdt:P2093
Robert Iannone S Peter Kang Peter Boasberg Scot W Ebbinghaus Omid Hamid Kevin Gergich Caroline Robert Hassane Zarour Amita Patnaik Michael A Postow Christine Mateus Wen-Jen Hwu Xiaoyun Nicole Li Jeroen Elassaiss-Schaap
wdt:P3181
42134
rdfs:label
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
skos:prefLabel
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
schema:name
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
p:P50
wds:Q29620814-773CAF62-1AB5-4925-8D45-37AAB82D5830 wds:Q29620814-885CF739-E187-47DC-96AA-069B455A47BA wds:Q29620814-8B9304AD-2BAE-44DB-9900-3CF8CBD31370 wds:Q29620814-94708EC2-5743-4C66-BCA7-A41157F003CA wds:Q29620814-1AF3CBE4-97E0-457C-A12E-AA680F45F44E wds:Q29620814-3206E9F0-530E-46B4-9DE8-1775202D4F1A wds:Q29620814-365EE056-4A85-4402-8A76-5707CE6CFF99 wds:Q29620814-C6282DE2-25E2-4924-A02E-69378A9072EB wds:Q29620814-CEBEAC00-C059-491F-8D91-8EA0E4866E85 wds:Q29620814-CF9D2E12-C551-422D-8390-D53CFF5AE1D3 wds:Q29620814-F0F4AE99-A37F-4389-80C4-E8403B77D849
wdt:P50
wd:Q90321337 wd:Q38524195 wd:Q112876312 wd:Q32649618 wd:Q84698958 wd:Q88137705 wd:Q32649604 wd:Q58701896 wd:Q46460242 wd:Q49880375 wd:Q112885391
p:P1476
wds:Q29620814-EED3110F-82A4-4917-97D9-F6F8176980D6
wdt:P1476
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
p:P304
wds:Q29620814-577D81BD-6D6E-4294-8AAA-045774C10387
wdt:P304
1109-1117
p:P31
wds:Q29620814-B78BEDE1-5AF2-493F-A2B9-5344E6068690
wdt:P31
wd:Q13442814
p:P921
wds:Q29620814-222AD4AC-37DD-4A2C-A14B-BF38844C31E9 wds:Q29620814-A5560651-8B10-43A6-B192-E403D88A8D8E wds:Q29620814-BDEE8D56-82DD-48BA-B0CE-53D0D90B18D3
wdt:P921
wd:Q2459042 wd:Q13896859 wd:Q5452194
p:P698
wds:Q29620814-CA639B27-75EA-45C8-AD97-9B80404268DA
wdtn:P698
n9:25034862
wdt:P698
25034862
p:P1433
wds:Q29620814-1E61FC8A-3C06-4599-9064-AA9AD08C02F5
wdt:P1433
wd:Q939416
p:P433
wds:Q29620814-CA5BD367-3C4C-4794-8702-3EAEE27902E7
p:P478
wds:Q29620814-97603F29-CBD4-4F0A-AB4B-7D35E8A2DD7D
wdt:P433
9948
wdt:P478
384
p:P356
wds:Q29620814-90FC3251-53B9-4D68-A1C6-071D5DE60BD7
wdtn:P356
n13:S0140-6736(14)60958-2
wdt:P356
10.1016/S0140-6736(14)60958-2